Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PuriBlood Medical CoROCO:6847 +2.91%74 Gross Margin % is 30.38% as of Dec. 2025, which is 23% above its 10-year median of 24.75. GuruFocus rates ROCO:6847 with a GF Score™ of 74/100 and a GF Value™ of NT$66.17 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, PuriBlood Medical Co ranks worse than 62.37% on this metric.
The historical rank and industry rank for PuriBlood Medical Co's Gross Margin % or its related term are showing as below:
ROCO:6847'
s Gross Margin % Range Over the Past 10 Years
Min: -23.5 Med: 24.75 Max: 63.08
Current: 39.24
During the past 8 years, the highestGross Margin % of PuriBlood Medical Co was 63.08%. The lowest was -23.50%. And the median was 24.75%.
ROCO:6847's Gross Margin % is ranked worse than 62.37% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.14
vs ROCO:6847: 39.24
PuriBlood Medical Co had a gross margin of 30.38% for the quarter that ended in Dec. 2025 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for PuriBlood Medical Co was 1.70% per year.
PuriBlood Medical Co (ROCO:6847) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
PuriBlood Medical Co had a gross margin of 30.38% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
PuriBlood Medical Co Gross Margin % Related Terms
PuriBlood Medical Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for PuriBlood Medical Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6847 vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, PuriBlood Medical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuriBlood Medical Co Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PuriBlood Medical Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where PuriBlood Medical Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
PuriBlood Medical Co (ROCO:6847) has a Gross Margin % of 30.38% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on PuriBlood Medical Co and its competitors. This is 23% above median its historical median of 24.75. According to the industry distribution chart, PuriBlood Medical Co ranks #121 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 62.4%.
Is PuriBlood Medical Co's Gross Margin % too high?
PuriBlood Medical Co's current Gross Margin % of 30.38% is 23% above median its 10-year median of 24.75. The Medical Diagnostics & Research industry median Gross Margin % is 51.14. PuriBlood Medical Co's value of 30.38% is 40.6% below this industry median. Based on the distribution chart, PuriBlood Medical Co ranks #121 out of 194 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, PuriBlood Medical Co has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PuriBlood Medical Co's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PuriBlood Medical Co ranks #121 out of 194 companies for Gross Margin %. This places PuriBlood Medical Co in the lower half of its industry. The industry median Gross Margin % is 51.14. PuriBlood Medical Co's value of 30.38% is 40.6% below this benchmark. While the company's 10-year median is 24.75 vs. the industry median of 51.14, PuriBlood Medical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.14, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PuriBlood Medical Co's current Gross Margin % of 30.38% is 40.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on PuriBlood Medical Co and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PuriBlood Medical Co's current Gross Margin % is 30.38%, which is 23% above median its own 10-year median of 24.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuriBlood Medical Co stock overvalued right now?
Based on GuruFocus' analysis, PuriBlood Medical Co (ROCO:6847) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$66.17, compared to a current price of NT$77.70 — trading 17.4% above its estimated fair value. The current Gross Margin % is 30.38%, which is 23% above median its 10-year median of 24.75 and 40.6% below the Medical Diagnostics & Research industry median of 51.14. PuriBlood Medical Co's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For PuriBlood Medical Co (ROCO:6847), the current Gross Margin % is 30.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PuriBlood Medical Co (ROCO:6847) Overvalued in 2026?
Based on GuruFocus' analysis, PuriBlood Medical Co stock appears to be overvalued.
The current stock price of NT$77.70 is trading 17.4% above its estimated GF Value™ of NT$66.17.
GuruFocus considers PuriBlood Medical Co to be Modestly Overvalued.
Key valuation signals for ROCO:6847:
Gross Margin %: 30.38% (23% above median its 10-year median of 24.75)
GF Value™: NT$66.17 vs. price of NT$77.70 (17.4% above fair value)
Industry Position: 40.6% below the Medical Diagnostics & Research median (#121 of 194)
No single metric tells the full story. See the ROCO:6847 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PuriBlood Medical Co Ltd is engaged in developing solutions for leukoreduction, cell separation, and anti-fouling materials. Its technology protects to supports living beings from medical devices to daily protection. The products of the company include Leukoreduction, Cell Separation, and P-tex.
74GF Score
Get the complete analysis for ROCO:6847
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6847 has been successfully added to your 
